FAPI-based radiopharmaceuticals are a novel class of tracers, mainly used for PET imaging, which have demonstrated several advantages over [18F]FDG, especially in the case of low-grade or well-differentiated tumors. We conducted this systematic review to evaluate all the studies where a head-to-head comparison had been performed to explore the potential utility of FAPI tracers in clinical practice. FAPI-based radiopharmaceuticals have shown promising results globally, in particular in detecting peritoneal carcinomatosis, but studies with wider populations are needed to better understand all the advantages of these new radiopharmaceuticals.
Prostate cancer (PCa) is the most frequently diagnosed cancer worldwide and the second most common cause of cancer-related deaths among men. Progress in molecular imaging has magnified its clinical management; however, an unmet clinical need involves the identification of new imaging biomarkers that complement the gold standard of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in cases of clinically significant PCa that do not express PSMA. Fibroblast activation protein (FAP) is a type II transmembrane serine overexpressed in many solid cancers that can be imaged through quinoline-based PET tracers derived from an FAP inhibitor (FAPi). Preliminary results of FAPi application in PCa (in PSMA-negative lesions, and in comparison with fluorodeoxyglucose—FDG) are now available in the literature. FAP-targeting ligands for PCa are not limited to detection, but could also include therapeutic applications. In this preliminary review, we provide an overview of the clinical applications of FAPi ligands in PCa, summarising the main results and highlighting contemporary strengths and limitations.
Background/Objectives: [18F]FDG-PET is often used for staging thymic epithelial tumours (TETs). However, its prognostic role remains uncertain. The aim of this present systematic review and meta-analysis is to assess the prognostic value of baseline [18F]FDG-PET-derived semiquantitative parameters in predicting progression-free survival (PFS) in patients with TETs. Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Embase, and Scopus databases were searched up to 30 May 2025. Studies evaluating the prognostic impact of [18F]FDG-PET parameters on PFS in TETs were included. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Results: Six retrospective studies involving 593 patients were included. Maximum standardized uptake value (SUVmax), analysed as a continuous variable in four studies, significantly predicted worse PFS (HR: 1.18, 95% CI: 1.08–1.29, p < 0.001), with high inter-study heterogeneity (I2 = 79.7%). When dichotomized (two studies), higher SUVmax was associated with significantly poorer PFS (HR: 9.00, 95% CI: 2.93–27.71). Similarly, mean SUV (SUVmean) as a continuous predictor was also significantly associated with impaired PFS (HR: 1.41, 95% CI: 1.25–1.59), but only two studies assessed this parameter. Conversely, metabolic tumour volume (MTV) and total lesion glycolysis (TLG), both assessed as continuous prognosticators, did not show a significant prognostic value. Notably, in both MTV and TLG analyses, two studies contributed a weight of 0%, reflecting limited precision and highlighting the need for larger data. Conclusions: Baseline [18F]FDG-PET parameters such as SUVmax and SUVmean showed a potential prognostic value in patients with TETs. However, these results are based on a limited number of retrospective studies with significant heterogeneity. Prospective multicentre investigations are necessary to confirm the potential role of [18F]FDG-PET for risk stratification in TETs.